RNAZ TransCode Therapeutics: רווח למניה בשנים עשר החודשים האחרונים

TransCode Therapeutics (RNAZ) develops durable RNA-based drugs, banking on stable demand in oncology and high margins. These developments establish a patent base for future monetization, as evidenced by the change in per-unit profit over the last 12 months. The value of -50.79 reflects the current metric volume, while the market currently prices in capital dilution risks due to the absence of current commercial revenue.

Stability of RNA component supplies through diversified channels provides TransCode Therapeutics (RNAZ) with operational resilience. Net income per share (TTM) measures the final financial result distributed across all equity shares over the year. This metric allows for an assessment of real business efficiency by excluding distortions from share issuances. It is critical for investors to see whether technological superiority converts into actual earnings. Analyzing the annual TTM earnings per share helps determine the growth rate of margins.